Minerva Neurosciences, Inc. (NASDAQ:NERV) Short Interest Update

Minerva Neurosciences, Inc. (NASDAQ:NERV) was the recipient of a large growth in short interest in February. As of February 28th, there was short interest totalling 56,900 shares, a growth of 35.5% from the February 13th total of 42,000 shares. Based on an average trading volume of 43,600 shares, the short-interest ratio is currently 1.3 days. Approximately 1.1% of the shares of the company are sold short.

Minerva Neurosciences Stock Up 5.8 %

Shares of Minerva Neurosciences stock traded up $0.09 during midday trading on Tuesday, hitting $1.65. The company’s stock had a trading volume of 2,301 shares, compared to its average volume of 29,028. The firm has a market capitalization of $11.54 million, a P/E ratio of -3.75 and a beta of 0.10. The stock has a 50-day simple moving average of $2.00 and a 200-day simple moving average of $2.29. Minerva Neurosciences has a 1-year low of $1.42 and a 1-year high of $3.69.

Minerva Neurosciences (NASDAQ:NERV) last issued its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($1.05) by $0.49. As a group, sell-side analysts predict that Minerva Neurosciences will post -0.3 earnings per share for the current year.

Institutional Trading of Minerva Neurosciences

A hedge fund recently raised its stake in Minerva Neurosciences stock. Citadel Advisors LLC grew its stake in Minerva Neurosciences, Inc. (NASDAQ:NERV) by 49.5% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 25,764 shares of the biopharmaceutical company’s stock after buying an additional 8,525 shares during the period. Citadel Advisors LLC owned approximately 0.37% of Minerva Neurosciences worth $57,000 as of its most recent SEC filing. 34.56% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on NERV shares. HC Wainwright reiterated a “neutral” rating and set a $5.00 price target on shares of Minerva Neurosciences in a research report on Wednesday, February 26th. StockNews.com began coverage on Minerva Neurosciences in a report on Tuesday. They issued a “sell” rating on the stock.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.